PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25522268-9	2014	Rosiglitazone (RSG) attenuated HF diet-induced atherosclerotic plaque formation in ApoE(-/-) mice, accompanied by reduced expression of TLR4, proinflammatory cytokines and ACAT1 accordingly.	Rosiglitazone	0-13	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	172-177	
25522268-9	2014	Rosiglitazone (RSG) attenuated HF diet-induced atherosclerotic plaque formation in ApoE(-/-) mice, accompanied by reduced expression of TLR4, proinflammatory cytokines and ACAT1 accordingly.	Rosiglitazone	15-18	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	172-177	
23268412-6	2012	Rosiglitazone treatments significantly lowered the contents of total cholesterol and free cholesterol (P<0.05), decreased the expression of ACAT-1 (P<0.05), and increased SR-BI expression (P<0.05) in the foam cells in a dose-dependent manner.	Rosiglitazone	0-13	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	143-149	
23268412-7	2012	CONCLUSION: Rosiglitazone can decrease the contents of total and free cholesterol, down-regulate ACAT-1 expression and up-regulate SR-BI expression in the foam cells produce the anti-atherosclerotic effect.	Rosiglitazone	12-25	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	97-103